What rings are found in drugs?

Recently we highlighted the “Ring Replacement Recommender,” which provides suggestions for how to improve affinity by replacing one ring with another. The recommendations are based on an analysis of hundreds of thousands of molecules. But what about the rings found in actual drugs? This is the focus of a J. Med. Chem. paper by Richard Taylor and collaborators at UCB and Bohicket Pharma Consulting.

 

The researchers examined FDA-approved and investigational drugs with disclosed structures as of January 2020. These were fragmented into component “ring systems” for analysis. (Ring systems include not just monocycles but fused rings, such as purine. For example, sotorasib consists of four ring systems: benzene, pyridine, piperazine, and pyrido[2,3-d]pyrimidin-2-one.) More than 90% of drugs contain at least one ring.

 

Approved drugs have just 378 unique ring systems in total – a small increase from when the researchers examinedapproved drugs in 2014. The phenyl ring is found 727 times, with pyridyl (86 examples) a distant second, followed by piperidine (76 examples) piperazine (65 examples) and cyclohexane (47 examples). After that the numbers drop off sharply, with pyrazine in 50^th place with just six examples and fluorene in 100^thplace with three examples.

 

Investigational drugs at first appear to be more diverse, with 450 unique ring systems, 280 of which are not found in approved drugs. Of these 280, pyridazine is the most common, with nine examples, followed by oxetane, with seven, but things quickly become less common from there, with 271 of the ring systems found just once. In contrast, ring systems found in drugs are found in multiple compounds, and in fact two thirds of investigational drugs only contain previously used ring systems.

 

Many of the new ring systems are closely related to those found in approved drugs, with nearly half differing by at most two atoms. Perhaps because of this the overall properties of the ring systems are similar between approved and investigational drugs, with no significant differences in heteroatom ratio, percentage of sp³ centers, or number of rings per system.

 

What new opportunities exist? The researchers identified nearly half a million synthetically accessible ring systems and winnowed these down to 3902 ring systems that have similar heteroatom ratios to those found in drugs and differ by at most two atoms. This attempt to explore new chemical space is similar to earlier work from the same group (here) as well as that from others (here, here and here).

 

The researchers also examined growth vectors and combinations of rings, the latter by using graph theory. These analyses suggest that investigational drugs do have greater variety. In other words, even if the component rings are shared with approved drugs, they might be combined in new ways.

 

Whether certain ring systems are more likely to fail in the clinic was intentionally not addressed, due to the difficulty of assessing why the failures occurred. For example, drugs can fail for commercial reasons; a company may choose to drop a drug against a particular target rather than be tenth to market. And even when the failure is due to the science, it might not be an indictment of the drug itself. Verubecestat did lower β-amyloid levels in people as designed, but had no effect on Alzheimer’s disease.

 

This paper is a fun read, and it will likely provide ideas for scaffold hopping and library design. It is also a reminder of how much chemical space remains to be explored.